Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology
- PMID: 9412849
- DOI: 10.1007/BF02083302
Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology
Abstract
Since its introduction in the early '80s the use of botulinum toxin has improved the quality of life of the patients affected by movement disorders. Toxin's neuromuscular blocking action allows a symptomatic treatment of those clinical conditions characterised by excessive muscular activity. Although the dosages used are safe and the side-effects are reversible, a correct use of botulinum toxin depends on the knowledge of its clinical pharmacology and of the anatomy of the body segments to be injected. In addition, the treatment of more complex conditions, i.e. laringeal dystonia, imposes an inter-disciplinary approach and specialised injection techniques. In this review, the Italian Study Group on Movement Disorders presents the consensus guidelines for the therapeutic use of botulinum toxin in movement disorders. The main toxin types, their use and administration modalities, and the training guidelines will be presented.
Comment in
-
Guidelines for the therapeutic use of botulinum toxin in movement disorders.Ital J Neurol Sci. 1998 Jun;19(3):189-90. doi: 10.1007/BF00831571. Ital J Neurol Sci. 1998. PMID: 10933476 No abstract available.
Similar articles
-
Botulinum toxin in movement disorders.Neurol India. 2018 Mar-Apr;66(Supplement):S79-S89. doi: 10.4103/0028-3886.226441. Neurol India. 2018. PMID: 29503330 Review.
-
Botulinum toxin in movement disorders.Semin Neurol. 2007 Apr;27(2):183-94. doi: 10.1055/s-2007-971171. Semin Neurol. 2007. PMID: 17390263 Review.
-
Injectable neuromuscular blockade in the treatment of spasticity and movement disorders.J Child Neurol. 2003 Sep;18 Suppl 1:S50-66. doi: 10.1177/0883073803018001S0701. J Child Neurol. 2003. PMID: 13677571 Review.
-
An update on new and unique uses of botulinum toxin in movement disorders.Toxicon. 2018 Jun 1;147:84-88. doi: 10.1016/j.toxicon.2017.09.003. Epub 2017 Sep 6. Toxicon. 2018. PMID: 28888928 Review.
-
Diagnostic and therapeutic recommendations in adult dystonia: a joint document by the Italian Society of Neurology, the Italian Academy for the Study of Parkinson's Disease and Movement Disorders, and the Italian Network on Botulinum Toxin.Neurol Sci. 2022 Dec;43(12):6929-6945. doi: 10.1007/s10072-022-06424-x. Epub 2022 Oct 3. Neurol Sci. 2022. PMID: 36190683
Cited by
-
Severe Spastic Trismus without Generalized Spasticity after Unilateral Brain Stem Stroke.Ann Rehabil Med. 2012 Feb;36(1):154-8. doi: 10.5535/arm.2012.36.1.154. Epub 2012 Feb 29. Ann Rehabil Med. 2012. PMID: 22506250 Free PMC article.
-
Botulinum toxin for pain.Drugs R D. 2008;9(1):11-27. doi: 10.2165/00126839-200809010-00002. Drugs R D. 2008. PMID: 18095750 Free PMC article. Review.
-
Subjective assessment of effectiveness, quality of life, and psychological status of patients receiving botulinum toxin therapy for hemifacial spasm, blepharospasm, or cervical dystonia.Fujita Med J. 2021;7(1):12-17. doi: 10.20407/fmj.2019-027. Epub 2020 Jul 14. Fujita Med J. 2021. PMID: 35111538 Free PMC article.
-
Guidelines for the therapeutic use of botulinum toxin in movement disorders.Ital J Neurol Sci. 1998 Jun;19(3):189-90. doi: 10.1007/BF00831571. Ital J Neurol Sci. 1998. PMID: 10933476 No abstract available.
-
Botulinum Neurotoxins: History, Mechanism, and Applications. A Narrative Review.J Neurochem. 2025 Aug;169(8):e70187. doi: 10.1111/jnc.70187. J Neurochem. 2025. PMID: 40762356 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical